Compagnie Lombard Odier SCmA Sells 4,396 Shares of Zoetis Inc. $ZTS

Compagnie Lombard Odier SCmA lowered its stake in shares of Zoetis Inc. (NYSE:ZTS) by 25.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 13,215 shares of the company’s stock after selling 4,396 shares during the period. Compagnie Lombard Odier SCmA’s holdings in Zoetis were worth $1,663,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Tema Etfs LLC grew its stake in Zoetis by 3.1% in the fourth quarter. Tema Etfs LLC now owns 7,518 shares of the company’s stock valued at $946,000 after purchasing an additional 227 shares during the last quarter. Scharf Investments LLC lifted its position in shares of Zoetis by 65.7% during the fourth quarter. Scharf Investments LLC now owns 818,875 shares of the company’s stock valued at $103,032,000 after buying an additional 324,659 shares during the last quarter. Lodestone Wealth Management LLC purchased a new stake in shares of Zoetis during the fourth quarter valued at about $30,000. Frank Rimerman Advisors LLC boosted its holdings in shares of Zoetis by 12.5% in the 4th quarter. Frank Rimerman Advisors LLC now owns 4,134 shares of the company’s stock valued at $520,000 after buying an additional 459 shares in the last quarter. Finally, Three Seasons Wealth LLC grew its position in shares of Zoetis by 9.4% in the 4th quarter. Three Seasons Wealth LLC now owns 9,781 shares of the company’s stock worth $1,231,000 after buying an additional 838 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. William Blair reiterated an “outperform” rating on shares of Zoetis in a research note on Monday, March 2nd. Piper Sandler reaffirmed a “neutral” rating and issued a $135.00 price target (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. Barclays assumed coverage on Zoetis in a research report on Monday, December 8th. They set an “equal weight” rating and a $136.00 price target on the stock. Morgan Stanley set a $160.00 price objective on Zoetis in a research report on Thursday, December 18th. Finally, BTIG Research restated a “buy” rating and set a $160.00 target price on shares of Zoetis in a research note on Thursday, February 26th. Six investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Zoetis currently has an average rating of “Hold” and an average target price of $152.91.

Zoetis Trading Down 0.6%

NYSE ZTS opened at $117.45 on Thursday. Zoetis Inc. has a 12-month low of $113.29 and a 12-month high of $172.23. The company has a fifty day simple moving average of $122.97 and a two-hundred day simple moving average of $128.49. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. The stock has a market cap of $49.58 billion, a P/E ratio of 19.51, a P/E/G ratio of 1.80 and a beta of 0.95.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The firm had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. During the same period in the previous year, the company earned $1.40 earnings per share. The business’s quarterly revenue was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be issued a $0.53 dividend. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.8%. Zoetis’s dividend payout ratio is currently 35.22%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.